Souffle Therapeutics
Latest round
- Series B
Last raised
- Oct 2026
Total raised
- $335M
Investors
- 17
About Souffle Therapeutics
Based in Watertown, US, Souffle Therapeutics, Inc.Souffle Therapeutics, founded in 2021 and headquartered in Watertown, US, specializes in the development of targeted nucleic acid therapies. The firm has completed one deal to date, marking its entry into the biopharmaceutical sector. Souffle Therapeutics specializes in the development of nucleic acid medicines designed to precisely target and enter cells implicated in disease processes. The core product offerings focus on therapies for conditions such as Facioscapulohumeral Muscular Dystrophy (FSHD) and genetically driven cardiomyopathies, specifically targeting the phospholamban (PLN) gene mutation. These innovative treatments utilize engineered cell-specific ligands to facilitate the delivery of small interfering RNA (siRNA) across cell membranes, thereby modulating gene and protein levels to reverse disease states. Revenue generation is primarily structured through partnerships and collaborations with leading biotech and pharmaceutical companies focused on the development of genetic medicines. These transactions often involve B2B agreements, where Souffle provides its proprietary technology and expertise in nucleic acid therapies to enhance partners' product pipelines. The financial framework encompasses milestone payments and royalties associated with the commercialization of their therapies, ensuring a sustainable revenue stream while advancing their therapeutic offerings. Key products, including those targeting FSHD and PLN mutations, are anticipated to drive interest from healthcare providers and payers once they enter the market, highlighting the company's potential for long-term growth in the biopharmaceutical landscape. The company plans to initiate clinical trials for its therapies in 2026, with a strategic focus on expanding its presence in North America, Europe, and Asia, thereby addressing significant unmet medical needs in these regions.
Who invested in Souffle Therapeutics
17 investors across 2 rounds
See all investors in Souffle Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Souffle Therapeutics
Who invested in Souffle Therapeutics?
Souffle Therapeutics has 17 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Souffle Therapeutics raised?
Souffle Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Souffle Therapeutics last raise money?
Souffle Therapeutics's most recent round on record is a Series B, in Oct 2026.
What does Souffle Therapeutics do?
Based in Watertown, US, Souffle Therapeutics, Inc.
Where is Souffle Therapeutics headquartered?
Souffle Therapeutics is headquartered in Watertown, US.
Which VCs invest in companies like Souffle Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Souffle Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Souffle Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.